Ketoprofen ext-rel Caps Rx
Generic Name and Formulations:
Ketoprofen 200mg; ext rel; pH-dependent coated pellets in caps.
Various generic manufacturers
Indications for Ketoprofen ext-rel Caps:
Osteoarthritis. Rheumatoid arthritis.
Aspirin allergy. Late pregnancy. Coronary artery bypass graft surgery.
Advanced renal disease: not recommended. Acute pain. Renal or hepatic dysfunction. Edema. Hypertension. Cardiac failure. History of upper GI disease. Bleeding disorders. Hypoalbuminemia. Monitor blood, hepatic, renal, and ocular function in chronic use. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.
NSAID (propionic acid deriv.).
Avoid salicylates, probenecid. Renal toxicity potentiated with diuretics. Monitor oral anticoagulants. May increase toxicity of methotrexate. May increase serum lithium levels.
GI bleeding, peptic ulcer, peripheral edema, dyspepsia, headache, dizziness, drowsiness, nausea, abdominal pain, diarrhea, constipation, flatulence, rash (discontinue if occurs), tinnitus, visual disturbances, GI or CNS disturbances, nephrotoxicity, jaundice. See literature re: risk of cardiovascular events.
Formerly known under the brand name Oruvail.
Clinical Pain Advisor Articles
- FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Predictors of Opioid Overdose in High-Risk Users
- FDA to Review Long-Acting Treatment for Opioid Use Disorder
- Half of Patients Referred for Behavioral Treatment of Migraine Never Initiate Treatment
- Low-Dose Sumatriptan Injection Effective as Acute Migraine Treatment
- The Fight for Patient Privacy Under Big Data Analytics